First Hawaiian Bank Lowers Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

First Hawaiian Bank reduced its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 3.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,610 shares of the medical instruments supplier’s stock after selling 220 shares during the quarter. First Hawaiian Bank’s holdings in West Pharmaceutical Services were worth $2,177,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Evoke Wealth LLC acquired a new position in shares of West Pharmaceutical Services in the fourth quarter valued at about $7,770,000. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in West Pharmaceutical Services by 1.5% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 191,469 shares of the medical instruments supplier’s stock valued at $75,766,000 after purchasing an additional 2,759 shares during the period. International Assets Investment Management LLC grew its holdings in West Pharmaceutical Services by 13,230.0% in the fourth quarter. International Assets Investment Management LLC now owns 18,662 shares of the medical instruments supplier’s stock valued at $6,571,000 after purchasing an additional 18,522 shares during the period. Vanguard Group Inc. grew its holdings in West Pharmaceutical Services by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 9,002,632 shares of the medical instruments supplier’s stock valued at $3,170,007,000 after purchasing an additional 104,740 shares during the period. Finally, Mizuho Markets Americas LLC grew its holdings in West Pharmaceutical Services by 142.3% in the first quarter. Mizuho Markets Americas LLC now owns 29,628 shares of the medical instruments supplier’s stock valued at $11,724,000 after purchasing an additional 17,399 shares during the period. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO Eric Mark Green sold 66,000 shares of the business’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total value of $24,198,900.00. Following the completion of the sale, the chief executive officer now directly owns 152,908 shares of the company’s stock, valued at approximately $56,063,718.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP Silji Abraham sold 1,800 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total value of $595,404.00. Following the sale, the senior vice president now owns 2,860 shares in the company, valued at approximately $946,030.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Eric Mark Green sold 66,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total value of $24,198,900.00. Following the completion of the sale, the chief executive officer now owns 152,908 shares in the company, valued at approximately $56,063,718.20. The disclosure for this sale can be found here. 0.53% of the stock is currently owned by insiders.

West Pharmaceutical Services Trading Up 0.4 %

West Pharmaceutical Services stock traded up $1.32 during trading on Monday, reaching $301.60. 981,158 shares of the company were exchanged, compared to its average volume of 575,223. West Pharmaceutical Services, Inc. has a 52-week low of $265.00 and a 52-week high of $415.73. The company has a market capitalization of $21.97 billion, a P/E ratio of 39.61, a PEG ratio of 10.69 and a beta of 1.00. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.34 and a quick ratio of 1.68. The stock’s 50 day simple moving average is $320.53 and its two-hundred day simple moving average is $354.11.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.22). West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The business had revenue of $702.10 million for the quarter, compared to analyst estimates of $729.36 million. During the same period last year, the business earned $2.11 EPS. West Pharmaceutical Services’s revenue was down 6.9% compared to the same quarter last year. On average, equities research analysts expect that West Pharmaceutical Services, Inc. will post 6.44 earnings per share for the current fiscal year.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.